Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
0.8399
-0.0855 (-9.24%)
At close: Nov 20, 2026, 4:00 PM EST
0.8700
+0.0301 (3.58%)
After-hours: Nov 20, 2026, 7:51 PM EST
Palisade Bio Revenue
Palisade Bio had revenue of $500.00K in the twelve months ending September 30, 2026. That makes Palisade Bio the 44,589th largest company in the world by revenue and 6,347th in the United States.
Revenue (ttm)
$500.00K
Revenue Growth
n/a
P/S Ratio
301.15
Revenue / Employee
$35,714
Employees
14
Market Cap
150.58M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 250.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Abeona Therapeutics | 39.01M |
| ProQR Therapeutics | 23.46M |
| Pyxis Oncology | 11.04M |
| Whitehawk Therapeutics | 7.15M |
| Entrada Therapeutics | 3.98M |
| Oramed Pharmaceuticals | 2.00M |
| Sol-Gel Technologies | 1.44M |
| Korro Bio | 1.29M |
PALI News
- 10 days ago - Palisade Bio Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 10 days ago - Palisade Bio price target lowered to $16 from $25 at Piper Sandler - TheFly
- 10 days ago - Palisade Bio price target lowered to $5 from $7 at H.C. Wainwright - TheFly
- 11 days ago - Palisade Bio reports Q3 EPS (7c), consensus (6c) - TheFly
- 11 days ago - Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs - GlobeNewsWire
- 11 days ago - Palisade Bio Quarterly report: Q3 2026 - Filings
- 11 days ago - Palisade Bio Earnings release: Q3 2026 - Filings
- 24 days ago - Palisade Bio doses first patient in ASCENTRA-UC trial - TheFly